{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:15:23Z","timestamp":1777392923208,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2006,5,23]],"date-time":"2006-05-23T00:00:00Z","timestamp":1148342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00277-006-0137-x","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T13:48:44Z","timestamp":1148305724000},"page":"583-590","source":"Crossref","is-referenced-by-count":9,"title":["Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A)"],"prefix":"10.1007","volume":"85","author":[{"given":"Guzi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Wolfrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,5,23]]},"reference":[{"key":"137_CR1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","volume":"330","author":"R Alexanian","year":"1994","unstructured":"Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484\u2013489","journal-title":"N Engl J Med"},{"key":"137_CR2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91\u201397","journal-title":"N Engl J Med"},{"issue":"6 Suppl 17","key":"137_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/sonc.2002.34074","volume":"29","author":"B Barlogie","year":"2002","unstructured":"Barlogie B, Shaughnessy J, Zangari M, Tricot G (2002) High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol 29(6 Suppl 17):26\u201333 (Review)","journal-title":"Semin Oncol"},{"issue":"8","key":"137_CR4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.cdd.4400405","volume":"5","author":"GM Bokoch","year":"1998","unstructured":"Bokoch GM (1998) Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction? Cell Death Differ 5(8):637\u2013645","journal-title":"Cell Death Differ"},{"key":"137_CR5","first-page":"6846","volume":"61","author":"P Brossart","year":"2001","unstructured":"Brossart P, Schneider A, Dill P et al (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC-1 specific cytotoxic T-lymphocytes. Cancer Res 61:6846\u20136850","journal-title":"Cancer Res"},{"key":"137_CR6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.leu.2400714","volume":"11","author":"RD Brown","year":"1997","unstructured":"Brown RD, Yuen E, Nelson M, Gibson J, Joshua D (1997) The prognostic significance of T cells receptor beta gene rearrangements and idiotype-reactive T cell in multiple myeloma. Leukemia 11:1312\u20131317","journal-title":"Leukemia"},{"issue":"5","key":"137_CR7","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2004-01-0366","volume":"105","author":"C Choi","year":"2005","unstructured":"Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, Ho A, Schirrmacher V, Goldschmidt H, Beckhove P (2005) Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 105(5):2132\u20132134","journal-title":"Blood"},{"key":"137_CR8","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.202491499","volume":"99","author":"MV Dhodapkar","year":"2002","unstructured":"Dhodapkar MV, Krasovsky J, Olson K (2002) T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 99:13009\u201313013","journal-title":"Proc Natl Acad Sci USA"},{"key":"137_CR9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","volume":"197","author":"MV Dhodapkar","year":"2003","unstructured":"Dhodapkar MV, Geller MD, Chang DH et al (2003) A reversible defect in Natural Killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667\u20131676","journal-title":"J Exp Med"},{"key":"137_CR10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","volume":"11","author":"MV Dhodapkar","year":"2003","unstructured":"Dhodapkar MV, Krasovsky J, Osman K, Geller M (2003) Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 11:1753\u20131757","journal-title":"J Exp Med"},{"key":"137_CR11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","volume":"2002","author":"M Dudley","year":"2002","unstructured":"Dudley M, Wunderlich J, Robbins K et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002:850\u2013854","journal-title":"Science"},{"key":"137_CR12","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.4049\/jimmunol.153.9.4281","volume":"153","author":"F Farace","year":"1994","unstructured":"Farace F, Orlanducci F, Dietrich PY et al (1994) T cell repertoire in patients with B chronic lymphocytic leukemia. J Immunol 153:4281\u20134283","journal-title":"J Immunol"},{"key":"137_CR13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/86523","volume":"7","author":"M Feuerer","year":"2001","unstructured":"Feuerer M, Beckhove P, Bai L et al (2001) Therapy of human tumors in NOD\/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7:452\u2013458","journal-title":"Nat Med"},{"issue":"Suppl 5","key":"137_CR14","first-page":"S27","volume":"11","author":"H Goldschmidt","year":"1997","unstructured":"Goldschmidt H, Hegenbart U, Wallmeier M, Moos M, Haas R (1997) High-dose chemotherapy in multiple myeloma. Leukemia 11(Suppl 5):S27\u2013S531","journal-title":"Leukemia"},{"key":"137_CR15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","volume":"10","author":"W Gregory","year":"1992","unstructured":"Gregory W, Richards M, Malpas J (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10:334\u2013342","journal-title":"J Clin Oncol"},{"key":"137_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0609.1999.tb01757.x","volume":"62","author":"M Hjorth","year":"1999","unstructured":"Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Wisloff F (1999) Survival in conventionally treated younger (<60\u00a0years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG). Eur J Haematol 62:271\u2013277","journal-title":"Eur J Haematol"},{"key":"137_CR17","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1182\/blood.V77.8.1776.1776","volume":"77","author":"CH Janson","year":"1991","unstructured":"Janson CH, Grunewald J, \u00d6sterborg A, Dersimonian H, Brenner MB, Mellstedt H, Wigzell H (1991) Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 77:1776\u20131780","journal-title":"Blood"},{"key":"137_CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/10428199909093733","volume":"33","author":"N Kay","year":"1999","unstructured":"Kay N, Leong T, Kyle RA et al (1999) Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma 33:127\u2013133","journal-title":"Leuk Lymphoma"},{"key":"137_CR19","first-page":"214","volume":"73","author":"M Massaia","year":"1988","unstructured":"Massaia M, Dianzani U, Bianchi A, Camponi A, Boccasoro M, Pileri A (1988) Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin Exp Immunol 73:214\u2013218","journal-title":"Clin Exp Immunol"},{"key":"137_CR20","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood.V87.8.3297.bloodjournal8783297","volume":"87","author":"P Moss","year":"1996","unstructured":"Moss P, Gillespie G, Frodsham P, Bell J, Reyburn H (1996) Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood 87:3297\u20133306","journal-title":"Blood"},{"key":"137_CR21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1006\/bbrc.1999.0683","volume":"258","author":"T Ohtomo","year":"1999","unstructured":"Ohtomo T, Sugamata Y, Ozaki Y et al (1999) Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 258:583\u2013591","journal-title":"Biochem Biophys Res Commun"},{"key":"137_CR22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P","volume":"30","author":"C Pellat-Deceunynck","year":"2000","unstructured":"Pellat-Deceunynck C, Mellerin MP, Labarriere N et al (2000) The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 30:803\u2013809","journal-title":"Eur J Immunol"},{"issue":"5318","key":"137_CR23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1126\/science.276.5318.1571","volume":"276","author":"T Rudel","year":"1997","unstructured":"Rudel T, Bokoch GM (1997) Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276(5318):1571\u20131574","journal-title":"Science"},{"issue":"1","key":"137_CR24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4049\/jimmunol.160.1.7","volume":"160","author":"T Rudel","year":"1998","unstructured":"Rudel T, Zenke FT, Chuang TH, Bokoch GM (1998) p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells. J Immunol 160(1):7\u201311","journal-title":"J Immunol"},{"issue":"5","key":"137_CR25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1006\/bcmd.2001.0452","volume":"27","author":"M Simons-Evelyn","year":"2001","unstructured":"Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D, Rapoport AP (2001) PBK\/TOPK is a novel mitotic kinase which is upregulated in Burkitt\u2019s lymphoma and otherhighly proliferative malignant cells. Blood Cells Mol Diseases 27(5):825\u2013829","journal-title":"Blood Cells Mol Diseases"},{"key":"137_CR26","first-page":"1398","volume-title":"Hematology: principles and practice","author":"G Tricot","year":"2000","unstructured":"Tricot G (2000) Multiple myeloma. In: Hoffmann R (ed) Hematology: principles and practice. Churchill Livingstone, New York, pp 1398\u20131415"},{"issue":"6","key":"137_CR27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/76243","volume":"6","author":"A Trojan","year":"2000","unstructured":"Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6(6):667\u2013672","journal-title":"Nat Med"},{"key":"137_CR28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1084\/jem.180.4.1283","volume":"180","author":"TJ Tsomides","year":"1994","unstructured":"Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN (1994) Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 180:1283\u20131293","journal-title":"J Exp Med"},{"key":"137_CR29","first-page":"1156","volume":"94","author":"N Baren van","year":"1999","unstructured":"van Baren N, Brasseur F, Godelaine D et al (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94:1156\u20131164","journal-title":"Blood"},{"key":"137_CR30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1084\/jem.171.3.659","volume":"171","author":"T Wen","year":"1990","unstructured":"Wen T, Mellstedt H, Jondal M (1990) Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 171:659\u2013666","journal-title":"J Exp Med"},{"key":"137_CR31","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood.V97.6.1750","volume":"97","author":"YJ Wen","year":"2001","unstructured":"Wen YJ, Barlogie B, Yi Q (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97:1750\u20131755","journal-title":"Blood"},{"key":"137_CR32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2141.1997.d01-2021.x","volume":"96","author":"Q Yi","year":"1997","unstructured":"Yi Q, Eriksson I, He W, Holm G, Mellstedt H, \u00d6sterborg A (1997) Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. Br J Haematol 96:338\u2013345","journal-title":"Br J Haematol"},{"issue":"5","key":"137_CR33","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","volume":"99","author":"F Zhan","year":"2002","unstructured":"Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745\u20131757","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0137-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-006-0137-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-006-0137-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T13:30:12Z","timestamp":1683466212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-006-0137-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,23]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1007\/s00277-006-0137-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,23]]}}}